Tchem PADI2 Protein-arginine deiminase type-2

Protein Summary

Description

Catalyzes the deimination of arginine residues of proteins. This gene encodes a member of the peptidyl arginine deiminase family of enzymes, which catalyze the post-translational deimination of proteins by converting arginine residues into citrullines in the presence of calcium ions. The family members have distinct substrate specificities and tissue-specific expression patterns. The type II enzyme is the most widely expressed family member. Known substrates for this enzyme include myelin basic protein in the central nervous system and vimentin in skeletal muscle and macrophages. This enzyme is thought to play a role in the onset and progression of neurodegenerative human disorders, including Alzheimer disease and multiple sclerosis, and it has also been implicated in glaucoma pathogenesis. This gene exists in a cluster with four other paralogous genes. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• Q9Y2J8
• Q96DA7
• Q9UPN2

Gene Name

• PADI2

Ensembl ID

• ENST00000375481
• ENSP00000364630
• ENSG00000117115
• ENST00000375486
• ENSP00000364635

Symbol

• KIAA0994
• PAD2
• PDI2
• PAD2
• PDI2
• PAD-H19

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
gene perturbation	0.95
disease perturbation	0.93
biological process	0.9
protein domain	0.73
PubMedID	0.71

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 311.46   (req: < 5)

Gene RIFs: 60   (req: <= 3)

Antibodies: 242   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 311.46   (req: >= 5)

Gene RIFs: 60   (req: > 3)

Antibodies: 242   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 15

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 4

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0